Related Experiment Video
Updated: Aug 23, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity
Melissa L Fishel1, David R Newell, Roger J Griffin
1Department of Medicine, Committe on Cancer Biology and Cancer Research Center, University of Chicago, Chicago, IL 60637, USA.
Abstract:
Pharmacological inhibitors of cyclin-dependent kinase (CDK)2 are currently in preclinical and clinical development. The purpose of our work was to evaluate a series of guanine derivatives for their ability to inhibit CDK2, affect cell cycle progression, and enhance the cytotoxic and apoptotic effects of cisplatin. A panel of guanine derivatives, including O(6)-benzylguanine (O(6)-BG), S(6)-benzyl-6-thioguanine (S(6)-BG), S(6)-[(cyclohexyl)methyl]-6-thioguanine (S(6)-CMG), O(6)-[(cyclohexyl)methyl]guanine (O(6)-CMG), O(6)-benzyl-9-methylguanine (9-CH(3)-BG), O(6)-[(cyclohexyl)methyl]-9-methyl-guanine (9-CH(3)-CMG), and 7-benzylguanine (N7-BG), exhibited varying degrees of CDK2 inhibition with O(6)-CMG being the most potent and 9-CH(3)-BG, 9-CH(3)-CMG, and N7-BG the least potent compounds. Treatment with S(6)-CMG and O(6)-CMG significantly decreased the percentage of cells in S phase. In SQ20b and SCC61 head and neck cancer cell lines, the most potent CDK2 inhibitor, O(6)-CMG, was also the most effective at enhancing cisplatin-induced cytotoxicity and apoptosis. Cisplatin-induced DNA platination increased in SQ20b cells pretreated with S(6)-BG, S(6)-CMG, and O(6)-CMG. Treatment with both O(6)-BG and trichostatin A, an indirect cell cycle inhibitor, demonstrated additive effects on cisplatin-induced cytotoxicity. In summary, we have identified a group of guanine derivatives that were effective modulators of cisplatin-induced cytotoxicity and apoptosis.
Insights
Researchers explored guanine derivatives as inhibitors of cyclin-dependent kinase 2 (CDK2). Certain derivatives enhanced cisplatin
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinase 2 (CDK2) inhibitors are under investigation for cancer therapy.
- Guanine derivatives represent a potential class of small molecules targeting CDK2.
Purpose of the Study:
- To assess guanine derivatives for CDK2 inhibition.
- To evaluate their impact on cell cycle progression.
- To determine their ability to enhance cisplatin's cytotoxic and apoptotic effects.
Main Methods:
- Synthesized and screened a panel of guanine derivatives for CDK2 inhibitory activity.
- Assessed effects on cell cycle progression, specifically S phase.
- Evaluated enhancement of cisplatin-induced cytotoxicity and apoptosis in head and neck cancer cell lines (SQ20b, SCC61).
- Measured cisplatin-induced DNA platination.
Main Results:
- O(6)-CMG demonstrated the highest CDK2 inhibitory potency.
- S(6)-CMG and O(6)-CMG significantly reduced the percentage of cells in S phase.
- O(6)-CMG enhanced cisplatin-induced cytotoxicity and apoptosis most effectively.
- S(6)-BG, S(6)-CMG, and O(6)-CMG increased cisplatin-induced DNA platination.
Conclusions:
- Guanine derivatives, particularly O(6)-CMG, are potent CDK2 inhibitors.
- These compounds modulate cell cycle progression and enhance cisplatin's anti-cancer effects.
- Identified guanine derivatives as effective modulators of cisplatin-induced cytotoxicity and apoptosis in cancer cells.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...

